

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION

Inventor(s): CHOO et al.

Appln. No.: 09 424,487

Series Code ↑ Serial No. ↑

Filed: February 29, 2000

Hon. Commissioner of Patents
Washington, D.C. 20231

Group Art Unit 1653

Examiner: D. Srivastava

Atty. Dkt. PM 264975

P002580USP

Appln. Title: NUCLEIC ACID BINDING PROTEINS

RECEIVED

05 2001

Sir:

REPLY/LETTER

Date: December 28, 2000

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated herein by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim A. <input type="checkbox"/> NOT made B. <input type="checkbox"/> Withdrawn C. <input type="checkbox"/> made herewith D. <input checked="" type="checkbox"/> made previously		For B & C See Required Separate Paper (Pat-256)		Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
2. Total Effective Claims				44	**minus 44	0	x \$18/\$9 =	+ \$0	103/203
3. Independent Claims				3	***minus 3	0	x \$80/\$40 =	+ \$0	102/202
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application)				add			+ \$270/\$135 =	+ \$0	104/204
5. Original due Date: October 28, 2000				<input type="checkbox"/> NONE					
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached				(1 mo)	\$110/\$55 =				115/215
				(2 mos)	\$390/\$195 =		+ \$195		116/216
				(3 mos)	\$890/\$445 =				117/217
				(Usable only for ≤ 2mo.OA --- 4 mos)	\$1390/\$695 =				118/218
				(Usable only for 30 day/1mo.OA --- 5 mos)	\$1890/\$945 =				128/228
7. Enter any previous extension fee paid since above original due date and subtract						- \$0			
8.						Extension Fee Attached		+ \$195	
9. If Terminal Disclaimer attached, add Rule 20(d) official fee						+ \$110/\$55		+ \$0	148/248
10. If IDS attached requires Official Fee under Rule 97 (c),				add		+ \$180		+ \$0	126
or if Rule 97(d) Request				add		+ \$180			126
11. After-Final Request Fee per rules 129(a) and 17(r)						+ \$710/355		+ \$0	146/246
12. No. of additional inventions for examination per Rule 129(b).....						x \$710/355 ea		+ \$0	149/249
13. Request for Continued Examination (RCE)						+ \$710/355		+ \$0	1179/1279
14. Petition fee for								+ \$0	

15.

TOTAL FEE ENCLOSED = \$195 RECEIVED

16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

Our Deposit Account No. 03-3975)

(Our Order No. 71278 264975

C#

M#

TECH CENTER 1600/2900

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Madison & Sutro LLP
Intellectual Property Group

By Atty: Perry E. Van Over

Sig:

Reg. No. 42197

Fax: (202) 822-0944

Tel: (202) 861-3545

1100 New York Avenue, NW
Ninth Floor
Washington, DC 20005-3918
Tel: (202) 861-3000
Atty/Sec: PEV/MJG

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: The claims and specification contains nucleic/amino acid sequences that have not been identified by the appropriate sequence identifier.


Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216 or (703) 308-2923
- For CRF Submission Help, call (703) 308-4212
- For PatentIn software Program Support:
 - HELP DESK: (703) 739-8559, ext 508, M-F, 8 AM to 5 PM EST except holidays
 - Email: PATIN21HELP@uspto.gov
 - To purchase PatentIn software: (703) 306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE



RECEIVED
05 2001
CENTER 1600/2900

RECEIVED

JAN 10 2001

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE — 05 2000


In re PATENT APPLICATION of

CHOO et al.

Application No.: 09/424,487

Filed: February 29, 2000

Title: NUCLEIC ACID BINDING PROTEINS



Group Art Unit: 1653

Examiner: D. Srivastava

RECEIVED

JAN 10 2001

TECH CENTER 1600/2900

* * * * *

December 28, 2000

SUBMISSION PURSUANT TO 37 CFR 1.821-1.825

C/12
1/16/01

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the Office Action dated September 28, 2000, and in order to comply with the requirements for patent applications containing nucleic acid sequence and/or amino acid sequence disclosures, please amend the above-referenced application as follows.

IN THE SPECIFICATION

Page 7, line 30, after "+2" insert --is--.

Page 9, line 8, after "structure:" insert --(SEQ ID NO: 3)--

line 16, after "structure:" insert --(SEQ ID NO: 4)--

Page 12, line 11, after "R T H T G" insert -- (SEQ ID NO: 5)--

line 12, after "T G E K P" insert -- (SEQ ID NO: 6)--

Page 28, line 30, after "-GCG-3'" insert --(SEQ ID NO: 7)--